Holen Sie sich die Stockscreener-App
1.30
3.17%
0.04
Handel nachbörslich:
1.27
-0.03
-2.31%
Schlusskurs vom Vortag:
$1.26
Offen:
$1.3
24-Stunden-Volumen:
680.93K
Relative Volume:
0.18
Marktkapitalisierung:
$57.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.325
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
-2.99%
1M Leistung:
+22.64%
6M Leistung:
-16.13%
1J Leistung:
-78.51%
1-Tages-Spanne:
$1.23
$1.31
1-Wochen-Bereich:
$1.221
$1.37
52-Wochen-Spanne:
$0.79
$6.98
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Vergleichen Sie OTLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.30 | 55.97M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Can Outlook Therapeutics Inc. stock beat analyst upgradesJuly 2025 Setups & Weekly High Return Forecasts - newser.com
Outlook Therapeutics (OTLK) Re-Submits BLA for Key Eye Treatment - GuruFocus
Outlook Therapeutics resubmits BLA for wet AMD treatment - Investing.com
How Outlook Therapeutics Inc. (41ON) stock compares with tech leadersQuarterly Profit Review & Stock Portfolio Risk Control - newser.com
How Outlook Therapeutics Inc. stock reacts to Fed rate cutsQuarterly Profit Report & Free Technical Confirmation Trade Alerts - newser.com
Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 to FDA for Wet AMD Treatment - Quiver Quantitative
Outlook Therapeutics Inc. stock prediction for this weekBond Market & Capital Efficiency Focused Ideas - newser.com
Outlook Therapeutics (Nasdaq: OTLK) re-submits BLA for LYTENAVA in wet AMD - Stock Titan
Is Outlook Therapeutics Inc. (41ON) stock worth buying before Fed actionLayoff News & Risk Controlled Stock Pick Alerts - newser.com
Will Outlook Therapeutics Inc. (41ON) stock enhance shareholder valueEarnings Recap Report & AI Driven Stock Reports - newser.com
Is Outlook Therapeutics Inc. stock a smart buy before Fed meetingWeekly Volume Report & Weekly Market Pulse Updates - newser.com
Is Outlook Therapeutics Inc. stock cheap at current valuationTrade Risk Report & Daily Price Action Insights - newser.com
What earnings margins imply for Outlook Therapeutics Inc. (41O) stockMarket Rally & Long-Term Growth Stock Strategies - newser.com
Why analysts upgrade Outlook Therapeutics Inc. stockForecast Cut & Technical Pattern Recognition Alerts - newser.com
Outlook Therapeutics Inc. stock momentum explainedMarket Activity Summary & Expert Verified Stock Movement Alerts - newser.com
Is Outlook Therapeutics Inc. (41O) stock bottoming after sell offTrade Volume Summary & Daily Chart Pattern Signals - newser.com
How to read the order book for Outlook Therapeutics Inc.Earnings Beat & Intraday High Probability Alerts - newser.com
Is Outlook Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
What technical models suggest about Outlook Therapeutics Inc.’s comebackWeekly Gains Summary & Real-Time Volume Spike Alerts - newser.com
What analysts say about Outlook Therapeutics Inc 41O stockResistance Zone Identification & Low Cost Wealth Strategies - earlytimes.in
Weiss Ratings Reiterates "Sell (D-)" Rating for Oncobiologics (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics Inc. stock chart pattern explainedMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
What drives Chordate Medical Holding AB publ K1Z0 stock priceFlag and Pennant Patterns & Market Crushing Stock Picks - earlytimes.in
Will Outlook Therapeutics Inc. (41ON) stock outperform value peersJuly 2025 Retail & Risk Controlled Stock Pick Alerts - newser.com
Full technical analysis of Outlook Therapeutics Inc. stockDip Buying & Fast Gain Swing Trade Alerts - newser.com
Is Outlook Therapeutics Inc. (41ON) stock testing key supportTrade Risk Assessment & Accurate Technical Buy Alerts - newser.com
What drives Outlook Therapeutics Inc 41ON stock priceREITs Market Trends & Rapid Portfolio Strategies - earlytimes.in
Outlook Therapeutics (OTLK) Price Target Increased by 11.90% to 9.59 - Nasdaq
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):